Literature DB >> 18997830

Outcome of allo-SCT for chronic myelomonocytic leukemia.

S Ocheni, N Kröger, T Zabelina, A R Zander, U Bacher.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18997830     DOI： 10.1038/bmt.2008.366

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics.

Authors:  Abhishek A Mangaonkar; Mrinal M Patnaik
Journal:  Adv Cell Gene Ther       Date:  2019-01-16

Review 2.  Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.

Authors:  Francesco Onida; Giovanni Barosi; Giuseppe Leone; Luca Malcovati; Enrica Morra; Valeria Santini; Giorgina Specchia; Sante Tura
Journal:  Haematologica       Date:  2013-09       Impact factor: 9.941

Review 3.  Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.

Authors:  Kristen B McCullough; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 4.  Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Authors:  Christopher B Benton; Aziz Nazha; Naveen Pemmaraju; Guillermo Garcia-Manero
Journal:  Crit Rev Oncol Hematol       Date:  2015-03-14       Impact factor: 6.312

Review 5.  Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management.

Authors:  Mrinal M Patnaik; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2018-06       Impact factor: 10.047

Review 6.  Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment.

Authors:  Giacomo Coltro; Mrinal M Patnaik
Journal:  Curr Oncol Rep       Date:  2019-11-14       Impact factor: 5.075

7.  Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.

Authors:  Piyanuch Kongtim; Uday Popat; Antonio Jimenez; Sameh Gaballa; Riad El Fakih; Gabriela Rondon; Julianne Chen; Carlos Bueso-Ramos; Gautam Borthakur; Naveen Pemmaraju; Guillermo Garcia-Manero; Hagop Kantarjian; Amin Alousi; Chitra Hosing; Paolo Anderlini; Issa F Khouri; Partow Kebriaei; Borje S Andersson; Betul Oran; Katayoun Rezvani; David Marin; Elizabeth J Shpall; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-04       Impact factor: 5.742

Review 8.  Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?

Authors:  Konstantinos Liapis; Ioannis Kotsianidis
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 9.  Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.

Authors:  Argiris Symeonidis; Spiros Chondropoulos; Evgenia Verigou; Vasileios Lazaris; Alexandra Kourakli; Panagiotis Tsirigotis
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

10.  Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms.

Authors:  Sung-Nam Lim; Je-Hwan Lee; Jung-Hee Lee; Dae-Young Kim; Sung Doo Kim; Young-A Kang; Young-Shin Lee; Kyoo-Hyung Lee
Journal:  Blood Res       Date:  2013-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.